What Can We Learn From AbCellera Biologics Inc. (ABCL)’s Valuation Ratios?


AbCellera Biologics Inc. (NASDAQ:ABCL) finished Wednesday with a subtraction of -$0.06 to close at $10.23, a downside of -0.58 percent. An average of 1,607,300 shares of common stock have been traded in the last five days. There was a fall of -$0.61 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,337,715 shares traded, while the 50-day average volume stands at 1,817,754.

ABCL stock has decreased by -7.08% in the last month. The company shares reached their 1-month lowest point of $9.80 on 09/19/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $5.42 and a high of $22.09 in 52 weeks. It has reached a new high 1 time so far this year and lost -28.46% or -$4.07 in price. In spite of this, the price is down -53.69% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Valuation Metrics

AbCellera Biologics Inc. (ABCL) has a trailing price-to-earnings (P/E) ratio of 16.03. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.04, the price-to-book (PB) ratio at 2.40, and the price-to-cash flow ratio at 10.69.

Financial Health

Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $170.79 million compared to revenue of $375.2 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, AbCellera Biologics Inc.’s return on assets was 14.10%.

Earnings Surprise

For the three-month period that ended March 30, AbCellera Biologics Inc. had $231.65 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$6.79 million in the quarter, while revenues of $168.57 million were grew 65.83%. The analyst consensus anticipated AbCellera Biologics Inc.’s latest quarter earnings to come in at $0.38 per share, but it turned out to be $0.54, a 42.10% surprise. For the quarter, EBITDA amounted to -$2.35 million. Shareholders own equity worth $285.14 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at AbCellera Biologics Inc. (ABCL) price momentum. RSI 9-day as of the close on 21 September was 35.35%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.00%.

As of today, ABCL’s price is $10.43 -5.63% or -$0.61 from its 5-day moving average. ABCL is currently trading -10.81% lower than its 20-day SMA and +29.82% higher than its 100-day SMA. However, the stock’s current price level is -10.18% below the SMA50 and -27.03% below the SMA200.

The stochastic %K and %D were 29.00% and 24.97%, respectively, and the average true range (ATR) was 0.53. With the 14-day stochastic at 24.29% and the average true range at 0.59, the RSI (14) stands at 40.47%. The stock has reached -0.36 on the 9-day MACD Oscillator while the 14-day reading was at -0.44.

Analyst Ratings

The Benchmark Company launched coverage on AbCellera Biologics Inc. (NASDAQ: ABCL) in its analyst report released on December 21, 2021. The firm assigned the stock a Buy rating.


Please enter your comment!
Please enter your name here